Myeloablative and Reduced-intensity conditioned Allogeneic Haematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of EBMT.
暂无分享,去创建一个
N. Kröger | L. Kanz | M. Robin | P. Chevallier | I. Yakoub-Agha | D. Niederwieser | D. Mclornan | M. Itälä-Remes | A. Radujkovic | G. Socié | E. Angelucci | M. Bornhäuser | J. Finke | Richard Szydlo | Y. Chalandon | M. Stelljes | A. Vítek | J. Hernández-Boluda | C. Wolschke | D. Beelen | V. Potter | P. Hayden | E. Klyuchnikov | L. Koster | T. Czerw | X. Poiré | E. Petersen | S. Robinson | Arnim Gerbitz | J. Hernández‐Boluda | A. Gerbitz
[1] M. Robin,et al. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019 , 2019, Haematologica.
[2] C. Harrison,et al. Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond. , 2017, Hematology. American Society of Hematology. Education Program.
[3] S. Chevret,et al. The Impact of Splenectomy in Myelofibrosis Patients before Allogeneic Hematopoietic Stem Cell Transplantation. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[4] R. Porcher,et al. Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] Francisco Cervantes,et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis , 2015, Haematologica.
[6] P. Johansson,et al. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries , 2012, Bone Marrow Transplantation.
[7] Jason Gotlib,et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.
[8] Francisco Cervantes,et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.
[9] N. Kröger,et al. Outcome of transplantation for myelofibrosis. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] B. Sandmaier,et al. Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[11] R. Fanin,et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) , 2008, Haematologica.